Imipenem/Cilastatin Hikma

Imipenem and cilastatin, the active ingredient in Imipenem/Cilastatin Hikma, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections in adult and pediatric patients when directed by a healthcare professional.

GNH USA supplies Imipenem/Cilastatin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Imipenem/Cilastatin is indicated for severe bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: eradication of susceptible pathogens causing peritonitis and intra‑abdominal sepsis. - Complicated urinary tract infections: treatment of infections caused by resistant Gram‑negative organisms. - Skin and soft‑tissue infections: management of serious cellulitis, abscesses and wound infections. - Community‑acquired and hospital‑acquired pneumonia: therapy for severe pneumonic infections due to susceptible bacteria. - Severe sepsis and septic shock: broad‑spectrum coverage in critically ill patients with systemic infection.

Like all antibiotics, Imipenem/Cilastatin may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild colitis - Headache - Rash or mild skin irritation - Infusion site pain or phlebitis

Serious or Rare Side Effects: - Seizures, especially in patients with CNS disorders - Anaphylaxis or severe allergic reactions - Clostridioides difficile‑associated colitis - Acute renal dysfunction - Thrombocytopenia or neutropenia - Elevated liver enzymes or hepatitis

Use Imipenem/Cilastatin with caution in specific clinical situations.

- Renal function: dose adjustment may be required in patients with impaired renal function. - Seizure risk: monitor patients with pre‑existing central nervous system disorders. - Allergy: avoid in individuals with known hypersensitivity to β‑lactam antibiotics. - Hepatic monitoring: observe liver enzymes during prolonged therapy. - Pregnancy and lactation: use only if the benefit outweighs the potential risk. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/Cilastatin can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concomitant use may reduce valproate levels and precipitate seizures. - Cimetidine or other renal dehydropeptidase inhibitors: may increase imipenem concentrations, raising toxicity risk. - Probenecid: can decrease renal clearance of imipenem, enhancing exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may increase the risk of nephrotoxicity. - Anticoagulants (e.g., warfarin): monitor INR as antibiotics can affect plasma protein binding. - Other broad‑spectrum antibiotics: assess for additive toxicity or antagonism.